Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of europe

Environmental Toxicology and Chemistry

Volumn 32, Issue 9, 2013, Pages 1954-1961

  Johnson, Andrew C ^a   Oldenkamp, Rik ^b   Dumont, Egon ^a   Sumpter, John P ^c  

^a CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Cytostatic; Cytotoxic drugs; Prediction; River; Sewage effluent

Indexed keywords

5-FLUOROURACIL; CYTOSTATIC; CYTOTOXIC DRUGS; ENVIRONMENTAL CONCENTRATION; EUROPEAN COUNTRIES; LIMITS OF DETECTION; SEWAGE EFFLUENTS; WATER CONCENTRATIONS;

FORECASTING; RIVERS; SEWAGE; WATER RESOURCES; WATER SUPPLY;

EFFLUENTS;

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; SURFACE WATER;

CHEMICAL ANALYSIS; CONCENTRATION (COMPOSITION); DRUG; EFFLUENT; POLLUTION MONITORING; REMOVAL EXPERIMENT; RIVER POLLUTION; RIVER WATER; WATER RESOURCE;

ARTICLE; CONCENTRATION (PARAMETERS); EUROPE; PREDICTION; PRIORITY JOURNAL; RIVER; SEWAGE EFFLUENT; SEWAGE TREATMENT; WATER ANALYSIS; WATER SUPPLY;

CYTOSTATIC; CYTOTOXIC DRUGS; PREDICTION; RIVER; SEWAGE EFFLUENT;

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENTS; DEOXYCYTIDINE; ENVIRONMENTAL MONITORING; EUROPE; FLUOROURACIL; RIVERS; SEWAGE; WATER POLLUTANTS, CHEMICAL;

EUROPE;

EID: 84880980755     PISSN: 07307268     EISSN: 15528618     Source Type: Journal    
DOI: 10.1002/etc.2311     Document Type: Article

References (69)

1. Daughton CG, Ternes TA. 1999. Pharmaceuticals and personal care products in the environment: Agents of subtle change? Environ Health Perspect 107:907-938.
2. Verlicchi P, Al Aukidy M, Zambello E. 2012. Occurrence of pharmaceutical compounds in urban wastewater: Removal, mass load and environmental risk after a secondary treatment: A review. Sci Total Environ 429:123-155.
3. Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159.
4. Sanderson H, Johnson DJ, Reitsma T, Brain RA, Wilson CJ, Solomon KR. 2004. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 39:158-183.
5. Besse JP, Latour JF, Garric J. 2012. Anticancer drugs in surface waters: What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs? Environ Int 39:73-86.
6. Rowney NC, Johnson AC, Williams RJ. 2009. Cytotoxic drugs in drinking water: A prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 28:2733-2743.
7. Kosjek T, Heath E. 2011. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Trends Anal Chem 30:1065-1087.
8. Zounkova R, Odraska P, Dolezalova L, Hilscherova K, Marsalek B, Blaha L. 2007. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 26:2208-2214.
9. Sanderson H, Brain RA, Johnson DJ, Wilson CJ, Solomon KR. 2004. Toxicity classification and evaluation of four pharmaceuticals classes: Antibiotics, antineoplastics, cardiovascular, and sex hormones. Toxicology 203:27-40.
10. Zounkova R, Kovalova L, Blaha L, Dott W. 2010. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 81:253-260.
11. Ternes TA, Meisenheimer M, McDowell D, Sacher F, Brauch HJ, Gulde BH, Preuss G, Wilme U, Seibert NZ. 2002. Removal of pharmaceuticals during drinking water treatment. Environ Sci Technol 36:3855-3863.
12. Huber MM, Gobel A, Joss A, Hermann N, Loffler D, McArdell CS, Ried A, Siegrist H, Ternes TA, von Gunten U. 2005. Oxidation of pharmaceuticals during ozonation of municipal wastewater effluents: A pilot study. Environ Sci Technol 39:4290-4299.
13. Kim I, Tanaka H. 2010. Use of ozone-based processes for the removal of pharmaceuticals detected in a wastewater treatment plant. Water Environ Res 82:294-301.
14. Cunningham VL, Binks SP, Olson MJ. 2009. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol 53:39-45.
15. Straub JO. 2010. Combined environmental risk assessment for 5-flourouracil and capecitabine in Europe. Integr Environ Assess Manag 6:540-566.
16. Collier AC. 2007. Pharmaceutical contaminants in potable water: Potential concerns for pregnant women and children. EcoHealth 4:164-171.
17. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H, Heyns L, Han SN, Tomek V, Mertens L, Ottevanger PB. 2012. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study. Lancet Oncol 13:256-264.
18. Cardonick E, Iacobucci A. 2004. Use of chemotherapy during human pregnancy. Lancet Oncol 5:283-291.
19. Calamari D, Zuccato E, Castiglioni S, Bagnati R, Fanelli R. 2003. Strategic survey of therapeutic drugs in the rivers Po and Lambro in northern Italy. Environ Sci Technol 37:1241-1248.
20. Metcalfe CD, Koenig BG, Bennie DT, Servos M, Ternes TA, Hirsch R. 2003. Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. Environ Toxicol Chem 22:2872-2880.
21. Kanda R, Griffin P, James HA, Fothergill J. 2003. Pharmaceutical and personal care products in sewage treatment works. J Environ Monit 5:823-830.
22. Thomas KV, Dye C, Schlabach M, Langford KH. 2007. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 9:1410-1418.
23. Gomez-Canela C, Cortes-Francisco N, Oliva X, Pujol C, Ventura F, Lacorte S, Caixach J. 2012. Occurrence of cyclophosphamide and epirubicin in wastewaters by direct injection analysis-liquid chromatography-high-resolution mass spectrometry. Environ Sci Pollut Res 19:3210-3218.
24. Busetti F, Linge KL, Heitz A. 2009. Analysis of pharmaceuticals in indirect potable reuse systems using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A 1216:5807-5818.
25. Tauxe-Wuersch A, de Alencastro LF, Grandjean D, Tarradellas J. 2006. Trace determination of tamoxifen and 5-fluorouracil in hospital and urban wastewaters. Int J Environ Anal Chem 86:473-485.
26. Colvin OM. 1999. An overview of cyclophosphamide development and clinical applications. Curr Pharm Design 5:555-560.
27. Chan KK, Hong PS, Tutsch K, Trump DL. 1994. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without Sr-2508. Cancer Res 54:6421-6429.
28. Kasel D, Jetter A, Harlfinger S, Gebhardt W, Fuhr U. 2004. Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18:1472-1478.
29. Kiffmeyer T, Gotze HJ, Jursch M, Luders U. 1998. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresen J Anal Chem 361:185-191.
30. Kümmerer K, Al-Ahmad A, Bertram B, Wiessler M. 2000. Biodegradability of antineoplastic compounds in screening tests: Influence of glucosidation and of stereochemistry. Chemosphere 40:767-773.
31. Buerge IJ, Buser HR, Poiger T, Muller MD. 2006. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 40:7242-7250.
32. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. 1984. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(ii) in patients with normal and impaired renal-function. Cancer Res 44:1693-1697.
33. Kummerer K, Helmers E, Hubner P, Mascart G, Milandri M, Reinthaler F, Zwakenberg M. 1999. European hospitals as a source for platinum in the environment in comparison with other sources. Sci Total Environ 225:155-165.
34. Grem JL. 2000. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299-313.
35. Reigner B, Blesch K, Weidekamm E. 2001. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104.
36. Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D, Bush E, Reigner B. 1999. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of C-14-labelled drug. Invest New Drugs 17:49-56.
37. Richards MA. 2006. Usage of cancer drugs approved by NICE: Report of review undertaken by the National Cancer Director. Gateway number 7124. Department of Health, London, UK.
38. Lenz K, Hann S, Koellensperger G, Stefanka Z, Stingeder G, Weissenbacher N, Mahnik SN, Fuerhacker M. 2005. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge. Sci Total Environ 345:141-152.
39. Coustere C, Mentre F, Sommadossi JP, Diasio RB, Steimer JL. 1991. A mathematical-model of the kinetics of 5-fluorouracil and its metabolites in cancer-patients. Cancer Chemother Pharmacol 28:123-129.
40. Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK. 2000. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol 18:915-926.
41. Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK. 2000. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol 11:1313-1322.
42. Guo XD, Harold N, Saif MW, Schuler B, Szabo E, Hamilton JM, Monahan BP, Quinn MG, Cliatt J, Nguyen D, Grollman F, Thomas RR, McQuigan EA, Wilson R, Takimoto CH, Grem JL. 2003. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 52:79-85.
43. Mahnik SN, Lenz K, Weissenbacher N, Mader RM, Fuerhacker M. 2007. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 66:30-37.
44. Dumont E, Williams R, Keller V, Voss A, Tattari S. 2012. Modelling indicators of water security, water pollution and aquatic biodiversity in Europe. Hydrolog Sci J 57:1378-1403.
45. Martin J, Camacho-Munoz D, Santos JL, Aparicio I, Alonso E. 2011. Simultaneous determination of a selected group of cytostatic drugs in water using high-performance liquid chromatography-triple-quadrupole mass spectrometry. J Sep Sci 34:3166-3177.
46. Yu JT, Bisceglia KJ, Bouwer EJ, Roberts AL, Coelhan M. 2012. Determination of pharmaceuticals and antiseptics in water by solid-phase extraction and gas chromatography/mass spectrometry: Analysis via pentafluorobenzylation and stable isotope dilution. Anal Bioanal Chem 403:583-591.
47. Sattelberger R. 1999. Arzneimittelruckstande in der umwelt: Bestandsaufnahme und problemdarstellung. Report R-162. Umweltbundesamt, Vienna, Austria.
48. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. 2002. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495-1501.
49. Al-Rawithi S, El-Yazigi A, Emst P, Al-Fiar F, Nicholls PJ. 1998. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Bone Marrow Transplant 22:485-490.
50. Joqueviel C, Martino R, Gilard V, Malet-Martino M, Canal P, Niemeyer U. 1998. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab Dispos 26:418-428.
51. Fasola G, Logreco P, Calori E, Zilli M, Verlicchi F, Motta MR, Ricci P, Baccarani M, Tura S. 1991. Pharmacokinetics of high-dose cyclophosphamide for bone-marrow transplantation. Haematologica 76:120-125.
52. Chen T-L, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Growchow LB. 1995. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy. Cancer Res 55:1600-1600.
53. Trump DL, Grem JL, Tutsch KD, Willson JKV, Simon KJ, Alberti D, Storer B, Tormey DC. 1987. Platinum analog combination chemotherapy: Cisplatin and carboplatin-A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 5:1281-1289.
54. Elferink F, Vandervijgh WJF, Klein I, Vermorken JB, Gall HE, Pinedo HM. 1987. Pharmacokinetics of carboplatin after IV administration. Cancer Treatment Reports 71:1231-1237.
55. Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL, Morstyn G. 1987. Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma. Cancer Chemother Pharmacol 19:326-330.
56. Mukherjee KL, Heidelberger C. 1960. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235:433-437.
57. Bernadou J, Armand JP, Lopez A, Maletmartino MC, Martino R. 1985. Complete urinary excretion profile of 5-fluorouracil during a 6-day chemotherapeutic schedule, as resolved by F-19 nuclear magnetic resonance. Clin Chem 31:846-848.
58. Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T, Weidekamm E. 1999. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 43:309-315.
59. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B. 1999. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:453-460.
60. Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, Tamura T, Takemiya S, Takiuchi H, Nakagawa K, Mishima H. 2006. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 36:410-417.
61. Kümmerer K, Al-Ahmad A. 1997. Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine, and gemcitabine: Impact of the chemical structure and synergistic toxicity with hospital effluent. Acta Hydrochimica Et Hydrobiologica 25:166-172.
62. Lenz K, Mahnik SN, Weissenbacher N, Mader RM, Krenn P, Hann S, Koellensperger G, Uhl M, Knasmuller S, Ferk F, Bursch W, Fuerhacker M. 2007. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci Technol 56:141-149.
63. Onesios KM, Bouwer EJ. 2012. Biological removal of pharmaceuticals and personal care products during laboratory soil aquifer treatment simulation with different primary substrate concentrations. Water Res 46:2365-2375.
64. Yu JT, Bouwer EJ, Coelhan M. 2006. Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent. Agric Water Manage 86:72-80.
65. Yin J, Yang Y, Li K, Zhang J, Shao B. 2010. Analysis of anticancer drugs in sewage water by selective SPE and UPLC-ESI-MS-MS. J Chromatogr Sci 48:781-789.
66. Garcia-Ac A, Segura P, Viglino L, Gagnon C, Sauvé S. 2011. Comparison of APPI, APCI and ESI for the LC-MS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater. J Mass Spectrom 46:383-390.
67. Hua WY, Bennett ER, Maio X-S, Metcalfe CD, Letcher RJ. 2006. Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. Environ Toxicol Chem 25:2356-2365.
68. Llewellyn N, Lloyd P, Jürgens MD, Johnson AC. 2011. Determination of cyclophosphamide and ifosfamide in sewage effluent by stable isotope-dilution liquid chromatography-tandem mass spectrometry. J Chromatogr A 1218:8519-8528.
69. Zuccato E, Castiglioni S, Fanelli R. 2005. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J Hazard Mater 122:205-209.